Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia
| Autor: | J Garcia Perlaza, J Vargas-Valencia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Neuroblastoma RAS viral oncogene homolog
Oncology medicine.medical_specialty Cetuximab business.industry Colorectal cancer Health Policy Wild type Public Health Environmental and Occupational Health medicine.disease medicine.disease_cause FOLFOX Internal medicine FOLFIRI Medicine Panitumumab KRAS business medicine.drug |
| Zdroj: | Value in Health. 18(7) |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2015.09.1188 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect